RU-28306: Difference between revisions

RU-28306
Identifiers
CAS Number	73625-11-3 ;
PubChem CID	194528;
ChemSpider	168785;
UNII	CT4LCW2PLE;
CompTox Dashboard (EPA)	DTXSID90994429 ;
Chemical and physical data
Formula	C13H16N2
Molar mass	200.285 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c13c(C2)cccc1[nH]cc3CC2N(C)C;
	InChI InChI=1S/C13H16N2/c1-15(2)11-6-9-4-3-5-12-13(9)10(7-11)8-14-12/h3-5,8,11,14H,6-7H2,1-2H3; Key:BQOANWOQEHVATQ-UHFFFAOYSA-N;

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 08:11, 19 September 2023

RU-28306 is a synthetic indole alkaloid derivative which acts as a serotonin receptor agonist, with selectivity for 5-HT₁ and 5-HT₂ subtypes. It can be regarded either as a tricyclic derivative of DMT, or a structurally simplified analogue of LSD, but the binding affinity of racemic RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT₂ subtypes and lower for 5-HT₁.^[1] It has been sold as a designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017.^[2]

References

^ Taylor EW, Nikam S, Weck B, Martin A, Nelson D (October 1987). "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences. 41 (16): 1961–9. doi:10.1016/0024-3205(87)90749-1. PMID 3657392.
^ EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA

[pmid3657392-1] Taylor EW, Nikam S, Weck B, Martin A, Nelson D (October 1987). "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences. 41 (16): 1961–9. doi:10.1016/0024-3205(87)90749-1. PMID 3657392.

[2] EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA

[1]

[2]

@@ Line 1: / Line 1: @@
+{{Short description|Chemical compound}}
 {{Drugbox
 | IUPAC_name =
-| image = RU-28306_structure.png
+| image = RU-28306.svg
 | width = 180
@@ Line 24: / Line 25: @@
 <!--Identifiers-->
+| CAS_number_Ref = {{cascite|correct|CAS}}
 | CAS_number = 73625-11-3
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = CT4LCW2PLE
 | ATC_prefix =
 | ATC_suffix =
 | PubChem = 194528
+| ChemSpiderID      = 168785
 <!--Chemical data-->
 | C=13 | H=16 | N=2
+| smiles = c13c(C2)cccc1[nH]cc3CC2N(C)C
-| molecular_weight = 200.279 g/mol
+| StdInChI          = 1S/C13H16N2/c1-15(2)11-6-9-4-3-5-12-13(9)10(7-11)8-14-12/h3-5,8,11,14H,6-7H2,1-2H3
-| smiles = c13c(C2)cccc1ncc3CC2N(C)C
+| StdInChIKey       = BQOANWOQEHVATQ-UHFFFAOYSA-N
 | melting_point =
 | melting_high =
 }}
-'''RU-28306''' is a tricyclic [[tryptamine]] derivative which acts as a [[serotonin receptor]] agonist, with selectivity for [[5-HT1 receptor|5-HT<sub>1</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub>]] subtypes. It can be regarded either as a conformationally constrained derivative of [[DMT]], or a structurally simplified analogue of [[LSD]], but the [[binding affinity]] of [[racemic]] RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT<sub>2</sub> subtypes and lower for 5-HT<sub>1</sub>.<ref>Taylor EW, Nikam S, Weck B, Martin A, Nelson D. Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites. ''Life Sciences''. 1987 Oct 19;41(16):1961-9. PMID 3657392</ref>
+'''RU-28306''' is a synthetic [[indole alkaloid]] derivative which acts as a [[serotonin receptor]] agonist, with selectivity for [[5-HT1 receptor|5-HT<sub>1</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub>]] subtypes. It can be regarded either as a tricyclic derivative of [[Dimethyltryptamine|DMT]], or a structurally simplified analogue of [[LSD]], but the [[binding affinity]] of [[racemic]] RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT<sub>2</sub> subtypes and lower for 5-HT<sub>1</sub>.<ref name="pmid3657392">{{cite journal | vauthors = Taylor EW, Nikam S, Weck B, Martin A, Nelson D | title = Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites | journal = Life Sciences | volume = 41 | issue = 16 | pages = 1961–9 | date = October 1987 | pmid = 3657392 | doi = 10.1016/0024-3205(87)90749-1 }}</ref> It has been sold as a [[designer drug]] and was first reported to the [[EMCDDA]] by a forensic laboratory in Slovenia in 2017.<ref>[http://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA]</ref>
 ==See also==
 * [[4,5-DHP-DMT]]
+* [[Bay R 1531]]
+* [[NDTDI]]
 * [[RU-24,969]]
@@ Line 51: / Line 60: @@
 [[Category:Serotonin receptor agonists]]
 [[Category:Tryptamines]]
+[[Category:Phenethylamines]]
+[[Category:Heterocyclic compounds with 3 rings]]
+[[Category:Indoles]]
+[[Category:Dimethylamino compounds]]